PL3424500T3 - Kompozycja farmaceutyczna zawierająca famitynib - Google Patents

Kompozycja farmaceutyczna zawierająca famitynib

Info

Publication number
PL3424500T3
PL3424500T3 PL17759210T PL17759210T PL3424500T3 PL 3424500 T3 PL3424500 T3 PL 3424500T3 PL 17759210 T PL17759210 T PL 17759210T PL 17759210 T PL17759210 T PL 17759210T PL 3424500 T3 PL3424500 T3 PL 3424500T3
Authority
PL
Poland
Prior art keywords
famitinib
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL17759210T
Other languages
English (en)
Inventor
Yun Lu
Xinhua Zhang
Chenyang Wang
Tonghui LIU
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of PL3424500T3 publication Critical patent/PL3424500T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL17759210T 2016-03-01 2017-02-28 Kompozycja farmaceutyczna zawierająca famitynib PL3424500T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610116472 2016-03-01
EP17759210.2A EP3424500B1 (en) 2016-03-01 2017-02-28 Pharmaceutical composition comprising famitinib
PCT/CN2017/075111 WO2017148359A1 (zh) 2016-03-01 2017-02-28 一种含有吡咯并六元杂环化合物或其可药用盐的药物组合物

Publications (1)

Publication Number Publication Date
PL3424500T3 true PL3424500T3 (pl) 2022-04-04

Family

ID=59743470

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17759210T PL3424500T3 (pl) 2016-03-01 2017-02-28 Kompozycja farmaceutyczna zawierająca famitynib

Country Status (17)

Country Link
US (1) US10973807B2 (pl)
EP (1) EP3424500B1 (pl)
JP (1) JP6948760B2 (pl)
KR (1) KR20180112066A (pl)
CN (1) CN107530331B (pl)
AU (1) AU2017226420B2 (pl)
BR (1) BR112018017155A2 (pl)
CA (1) CA3015249A1 (pl)
DK (1) DK3424500T3 (pl)
ES (1) ES2907376T3 (pl)
HU (1) HUE057830T2 (pl)
MX (1) MX380108B (pl)
PL (1) PL3424500T3 (pl)
PT (1) PT3424500T (pl)
RU (1) RU2737734C2 (pl)
TW (1) TWI750152B (pl)
WO (1) WO2017148359A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1973910T3 (pl) * 2006-01-27 2013-11-29 Shanghai hengrui pharmaceutical co ltd Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej
CN101007815B (zh) * 2006-01-27 2010-06-23 江苏恒瑞医药股份有限公司 吡咯并六元杂环化合物及其在医药上的用途
CN101007814A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯并六元杂环化合物及其在医药上的用途
EP2113248A1 (en) * 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CN102266300B (zh) * 2011-07-14 2013-01-02 广东药学院 一种吉非替尼分散片及其制备方法和应用

Also Published As

Publication number Publication date
KR20180112066A (ko) 2018-10-11
HUE057830T2 (hu) 2022-06-28
AU2017226420B2 (en) 2022-07-07
TWI750152B (zh) 2021-12-21
EP3424500A1 (en) 2019-01-09
PT3424500T (pt) 2022-02-07
RU2737734C2 (ru) 2020-12-02
EP3424500B1 (en) 2022-01-26
EP3424500A4 (en) 2019-10-02
WO2017148359A1 (zh) 2017-09-08
MX2018010272A (es) 2018-12-19
CN107530331B (zh) 2018-12-04
MX380108B (es) 2025-03-11
AU2017226420A1 (en) 2018-08-30
CN107530331A (zh) 2018-01-02
ES2907376T3 (es) 2022-04-25
DK3424500T3 (da) 2022-02-21
JP6948760B2 (ja) 2021-10-13
RU2018132929A (ru) 2020-04-01
CA3015249A1 (en) 2017-09-08
US10973807B2 (en) 2021-04-13
BR112018017155A2 (pt) 2018-12-26
JP2019507151A (ja) 2019-03-14
RU2018132929A3 (pl) 2020-05-13
TW201731508A (zh) 2017-09-16
US20190054073A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
IL265260B (en) pharmaceutical preparations
IL265360A (en) Pharmaceutical composition
IL262654A (en) Pharmacy preparation
IL269061A (en) A pharmaceutical preparation containing Selexifag
IL271986B1 (en) pharmaceutical preparation
IL265349A (en) Pharmaceutical composition
GB201521462D0 (en) Pharmaceutical composition
GB201712159D0 (en) Pharmaceutical composition
HUE068810T2 (hu) Gyógyászati készítmény
IL263040A (en) Pharmaceutical composition comprising eteplirsen
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
PL3646867T3 (pl) Kompozycja farmaceutyczna
PL3454838T3 (pl) Kompozycja farmaceutyczna
PT3463365T (pt) Formulação farmacêutica antifúngica
GB201615917D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
IL265436B (en) Pharmacy preparation
GB201615910D0 (en) Pharmaceutical composition
GB201620519D0 (en) Pharmaceutical composition
IL265428A (en) Pharmaceutical composition
PT3476391T (pt) Composição farmacêutica que compreende arginina para utilização no tratamento da doença de poliq
PL3329939T3 (pl) Stała kompozycja farmaceutyczna nienadająca się do nadużywania